Abbvie Inc ABBV

$264.34 -0.78 (-0.29%)

Valuation

Market cap
468,412,160,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.39
Forward PE
18.86
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
2,541,700
Avg volume
4,707,940
Day's range
$262.59 – $266.00
Shares out
1,766,793,000
Stochastic %K
56%
Beta
0.29
Analysts
Strong Sell
Price target
$277.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Gebinator Sep 26, 3:00 PM
Who sometimes reminisces the time we spent as kids getting up early to watch Saturday morning cartoons? It seems that ages and ions later some of us are re-living that Saturday morning feeling on ST! Anyhow, with various speculation about potential $SLS m&a activity, particularly with the established 'Top 3' - $JNJ, $MRK, $ABBV -- and with Simpson Healthcare now engaged to coordinate media and likely some of the m&a process, it may be worthwhile reviewing the field of 'dark horse' BP candidates having the ability to potentially out-bid the 'Top 3' - while also having the resources to fully develop GPS/SLS009. Considering the above, which one of the following BPs is the strongest 'dark horse' candidate for the $SLS prize 🏆 ?
1 replies
Merlintrader Sep 26, 9:09 AM
Ulcerative colitis: who can win room among the immunology giants? $ABBV, $ABVX, $JNJ, $SYRE https://www.merlintrader.com/ulcerative-colitis-abbv-abvx-jnj-syre/
1 replies
dagster01 Sep 26, 2:02 AM
$BMY $VKTX $NVO $ABBV IMO, it is smart for BL to move on and let the suitors conpete for his attention. Thry need Viking now more than Viking needs them.
0 replies
biolover Sep 26, 1:51 AM
$BMY $VKTX BL will not sell. It is obvious now. He will partner for the right deal. And agree BMY as desperate as novo. $NVO holders - some clueless and trash VK not realizing VK is a gift from heaven to save their company. Although I honestly believe when it is heated and the offer is close to final .: BMY , $ABBV or even Lilly will not make it easy on novo and they may snatch the deal.
2 replies
StocktwitsNews Sep 26, 1:02 AM
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines $NVO $LLY $NVS $ABBV https://stocktwits.com/news/equity/markets/biotech-deal-week-lilly-novo-and-novartis-pay-up-for-platforms-not-pipelines/cZMXysORBOn
0 replies
quassarcapital Sep 25, 10:54 PM
$ABBV (AbbVie) gets FDA approval for tavapadon (brand name Juvmo), a once-daily pill for Parkinson's disease, with the drug acquired through AbbVie's 2023 purchase of Cerevel Therapeutics.
0 replies
jheerdink Sep 25, 5:30 PM
$ABBV https://vistapglobal.com/serina-therapeutics-advances-ser-252-in-advanced-parkinsons-disease-as-continuous-therapy-market-expands-abbv-ser/
0 replies
SanKish Sep 25, 3:38 PM
$ABBV $AZN $PROK $TMO $VRTX that will be wonderful and a great help for multiple stakeholders - patients (because dialysis is painful and weakens heart over time), govt (because it is costly and too many additional Medicare expenses ) and hopefully hospitals and insurance companies ( if they are really thinking of saving their resources for better patient care).
1 replies